AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
Vyome Therapeutics Announces New Board with AI and MIT Ties Ahead of Public Listing
ByAinvest
Wednesday, Aug 13, 2025 4:34 am ET1min read
Vyome Therapeutics has announced a new Board of Directors, consisting of MIT alumni with expertise in AI and business, as it prepares for a public listing under the new name Vyome Holdings. The company will take over ReShape Lifesciences on August 15, 2025, and trade on the Nasdaq under the ticker symbol 'HIND'. The new board emphasizes shareholder interests and aims to leverage clinical-stage assets for transformative healthcare solutions.
Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases, has announced the composition of its new Board of Directors as it prepares for a public listing on August 15, 2025. The new board will take control of ReShape Lifesciences (NASDAQ: RSLS), which will be renamed Vyome Holdings, Inc. and trade under the ticker symbol HIND [1].The new board includes four members with ties to the Massachusetts Institute of Technology (MIT) and extensive experience in AI and business. The board members are:
- Krishna Gupta (Chairman), MIT engineering/business alum and CEO of Remus Capital, focused on Vertical AI applications in healthcare.
- Shiladitya Sengupta (Founder), MIT postgrad and serial entrepreneur, with a focus on medicine and engineering.
- Venkat Nelabhotla (Co-founder and CEO), IIM Ahmedabad alum, with 30+ years of experience in pharma, biotech, and CPG industries.
- Mohanjit Jolly (Shareholder), MIT alum and Partner of Iron Pillar, a seasoned investor with a focus on cutting-edge technology companies.
- John Tincoff (Shareholder), Georgetown alum and Partner at Remus Capital, with a focus on industrial applications and governance.
- Stash Pomichter (Shareholder), MIT engineering dropout and member of the Remus Capital team, with a focus on cutting-edge AI applications.
The new board emphasizes shareholder interests and aims to leverage Vyome's clinical-stage assets for transformative healthcare solutions. The company plans to trade on the Nasdaq under the ticker symbol HIND, following the merger with ReShape Lifesciences [2].
References:
[1] https://www.morningstar.com/news/business-wire/20250812232598/vyome-announces-new-board-of-directors-with-deep-mit-and-ai-ties
[2] https://www.biospace.com/press-releases/reshape-lifesciences-announces-shareholder-approval-of-merger-with-vyome-therapeutics
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet